Dr. John Warrick
-
Profile
Drosophilia models to study human polyglutamine diseases. Secondary interests include the study of neurogenetic behavior in Drosophila, especially circadian rhythms and visually driven behaviors.
Expand All-
Awards
Jeffress Memorial Trust, "CREB-binding Protein Modulation in a Drosophila Model of MJD and the Role of Chaperones"
National Institutes of Health, “Finding polyglutamine disease and rescue mechanisms using proteomic analysis”
-
Presentations
HHMI Research Introduction, October 21, 2010.
-
Awards
-
Publications
Journal Articles
Martin I., Jones M.A., Rhodenizer D., Zheng J., Warrick J.M., Seroude L., Grotewiel M. (2009) Sod2 knock-down in the musculature has whole organism consequences in Drosophila. Free Radic Biol Med;47(6):803-13.
Boeddrich A, Gaumer S, Haacke A, Tzvetkov N, Albrecht M, Evert BO, Muller EC, Lurz R, Breuer P, Schugardt N, Plassmann S, Xu K, Warrick JM, Suopanki J, Wullner U, Frank R, Hartl UF, Bonini NM, Wanker EE. (2006). An arginine/lysine-rich motif is crucial for VCP/p97-mediated modulation of ataxin-3 fibrillogenesis. EMBO J.; 25(7):1547-58
Warrick, J.M., Gordesky-Gold, B., Morabito, L., Faust, L., Paulson, H.L., and Bonini, N.M. (2005). Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol Cell: 18, 37-48.
Chan, H.Y.E*. and Warrick, J.M.*, Andriola, I., and Merry, D., and Bonini, N.M. (2002). Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila. Human Molecular Genetics 11 (23):2895-2904.